Close Menu

MEK inhibitors

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.

The assay examine phenotypic behaviors of isolated cancer cells from biopsies at initial diagnosis.

One of the first projects between the firms will be to develop and commercialize a companion diagnostic for the MEK inhibitor binimetinib in NRAS-mutant melanoma.

Before patients receive the Cotellic/Zelboraf combination, patients should be tested with an FDA-approved BRAF mutation companion test, the agency said.

"Seeing that we have had other agents in this class, there should be some sort of selection of tumor types, or some type of genomic profiling, or at least retainment of archival tissue, so that we can go on to profile these patients at a later date," said Patricia LoRusso of Karmanos Cancer Institute at Wayne State University, who reviewed early dosing trials of three MEK inhibitors being developed by GlaxoSmithKline, Merck Serono, and Eisai.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.